Study on sedation and analgesia of remitazolam combined with remifentanil in patients with cardiac insufficiency

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200065895

Enrollment

Unknown

Registered

2022-11-17

Start date

2022-12-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sedation and analgesia in patients with cardiac insufficiency

Interventions

Remazolam group:Remifentanil was given 0.1-0.4ug/kg/min for analgesia and 0.3mg/kg/h for sedation

Propofol group:Remifentanil 0.1-0.4ug/kg/min for analgesia and propofol 1mg/kg/h for sedation

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. After entering the ICU, the patients were given basic treatment such as maintaining circulation and respiratory support, and were given sedation and analgesia in time after being diagnosed with cardiac insufficiency; 2. Aged > 18 years; 3. Acute cardiac insufficiency or acute exacerbation of chronic cardiac insufficiency, NYHA grade III-IV; 4. Sedation and analgesia after admission to ICU are expected to be more than 6h.

Exclusion criteria

Exclusion criteria: 1. No sedation and analgesia; 2. Those who are allergic to the study drug; 3. Cases lost to follow-up shall be excluded.

Design outcomes

Primary

Measure	Time frame
Analgesia sedation delirium score;Respiratory support mode;Hemodynamic index;Blood gas analysis index;	—

Secondary

Measure	Time frame
Liver and kidney function, electrolyte;	—

Countries

China

Contacts

Public ContactMing Qiao

Renshou people's Hospital of Sichuan Province

781622670@qq.com+86 13890301687

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026